Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

As previously reported, Argus downgraded Biogen (BIIB) to Hold from Buy. The company has provided guidance for 2025, noting that it expects ...

Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

Organon’s workforce cuts come several months after the company’s loss of exclusivity to its second-largest product, Atozet.

Britain’s government is placing Russia on the top tier of a government security program aimed at protecting the U.K. from malign foreign influence. Home Office minister Dan Jarvis said anyone ...